Mode
Text Size
Log in / Sign up
Phase 2 N=29 Randomized Double-blind Treatment

Naltrexone and Hypoglycemia in Type 1 Diabetes

Type 1 Diabetes · Hypoglycemia Unawareness

Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Cerebral Blood Flow — 1.7; 1.3 percentage of signal intensity change

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Naltrexone (Drug); Placebo (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Minnesota
Primary completion
Jun 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Cerebral Blood Flow
1.7; 1.3
SECONDARY
Hypoglycemia Symptom Score
12.6; 14.5

Summary

Low blood sugar is also called hypoglycemia. Usually, it is mild and can be treated quickly and easily by eating or drinking a small amount of a sugar-rich food. If low blood sugar is left untreated, it can get worse and cause confusion, clumsiness or fainting. Severe hypoglycemia can lead to seizures, coma, and even death. Some people with diabetes do not have early warning signs of low blood sugar. This condition is called hypoglycemia unawareness. It happens when the body stops reacting to low blood sugar levels and the person does not realize that they need to treat their hypoglycemia. This can lead to more severe and dangerous hypoglycemia. The purpose of this early study is to see if a drug called naltrexone should be studied more in people with Type I diabetes and hypoglycemia unawareness. This study will show whether naltrexone could reduce hypoglycemia unawareness. The study will also show, by using magnetic resonance imaging (also called MRI), whether naltrexone changes the way blood flows in the brain when a person is experiencing hypoglycemia.

Eligibility Criteria

Inclusion Criteria

  • 18-65 years of age
  • Type 1 diabetes
  • Hypoglycemia unawareness
  • Capable of providing informed consent

Exclusion Criteria

  • Concomitant regular use of acetaminophen, aspirin or ibuprofen
  • History of drug or alcohol abuse
  • Psychiatric illness
  • Elevations in ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), creatinine or history of hepatitis, liver failure, or renal failure/insufficiency
  • Pregnant or breastfeeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01053078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search